Core Insights - The annual incidence of lung cancer in China reaches 1.06 million, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases, and the EGFR gene mutation being the most common driver gene with a mutation rate of about 50% [1] - There is a pressing demand for innovative treatment options with better efficacy and lower side effects for the large patient population [1] Group 1 - In August, JD Health signed a strategic cooperation agreement with Johnson & Johnson Innovation Pharmaceuticals to explore new product launches and academic exchanges, aiming to build a patient-centered healthcare service system [1] - JD Health will leverage its comprehensive pharmaceutical supply chain and nationwide distribution network to ensure that innovative specialty drugs, including Lico®, can safely and efficiently reach users across the country [1] Group 2 - On October 9, Johnson & Johnson's innovative targeted drug Lico® (lanzetini mesylate tablets) was launched online on JD Health, designed for first-line treatment of EGFR mutation-positive advanced NSCLC in combination with evinacumab [3] - Lico® offers significant survival benefits and safety advantages, providing a breakthrough treatment option for the large lung cancer patient population in China [3] - JD Health aims to enhance the accessibility of this innovative treatment solution, allowing more Chinese lung cancer patients to benefit from it as early as possible [3]

Core Insights - Johnson & Johnson's innovative targeted drug, Lico® (lanzetini mesylate tablets), has been launched online on JD Health, providing a breakthrough treatment option for a large population of lung cancer patients in China [1][2] - The drug is used in combination with evan monoclonal antibody for first-line treatment of EGFR mutation-positive advanced non-small cell lung cancer (NSCLC), offering significant overall survival benefits and safety advantages [1] - JD Health aims to enhance the accessibility of this innovative treatment through its "first station for new specialty drugs" capabilities, ensuring more lung cancer patients can benefit from it [1] Industry Context - According to the 2024 National Cancer Report, there are 1.06 million new lung cancer patients annually in China, with approximately 85% being non-small cell lung cancer [1] - The mutation rate of the EGFR gene, the most common driver gene in NSCLC, is about 50%, indicating a high demand for more effective and safer innovative treatment options [1] - In August, JD Health signed a strategic cooperation agreement with Johnson & Johnson's Innovative Pharmaceuticals to leverage JD Health's supply chain and service capabilities alongside Johnson & Johnson's innovative drug portfolio in oncology and other key disease areas [1]